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Diabetic Cardiomyopathy:
The Importance of Being Earliest*
Eugenio Picano, MD, PHD, FESC
Pisa, Italy
Over the years, the existence of a diabetic cardiomyopathy
distinct from ischemic injury has been confirmed (1), but
the challenge of recognizing diabetic cardiomyopathy at an
early stage, in a noninvasive way, still remains. In this issue
of the Journal, Fang et al. (2) evaluated 41 diabetic patients
and 41 matched control subjects with standard echocardio-
See page 446
graphic rest and dobutamine tissue Doppler-derived indices
of systolic and diastolic left ventricular (LV) function. In
that study, the diabetic patients, compared with control
subjects at rest, showed an impairment of peak myocardial
systolic velocity and early diastolic velocity. However, in the
diabetic group and in the control group, the dobutamine-
induced increases in both peak systolic and early diastolic
velocity were similar. The study comes from a well-known
laboratory and addresses an important, yet still elusive,
clinical target: the pre-clinical objective identification of
diabetic cardiomyopathy. The results obtained are interest-
ing, as the study outlines a novel approach for the identifi-
cation of early incipient diabetic cardiomyopathy, support-
ing the physician with suitable end points to test new
preventive and therapeutic approaches in these patients.
Diabetic cardiomyopathy: a heterogeneous entity. Diabetes
mellitus can provoke cardiac damage at different levels,
leading to the conditions known as coronary macrovascular
disease, autonomic dysfunction, diabetic cardiomyopathy,
and coronary microvascular disease (3). These syndromes
can be rarely found as isolated forms in individual patients
but rather often overlap and potentiate each other. In
particular, diabetes mellitus induces structural (4) and func-
tional (5,6) coronary microvascular abnormalities that are
associated with coronary endothelial dysfunction (7) and
with impairment in coronary flow reserve, even in the
absence of epicardial coronary artery disease. The coronary
microangiopathy component can amplify the effects of
coronary macroangiopathy, which is a major complication
of diabetes and can be important also for the progression of
cardiomyopathy (8). However, it can also be present inde-
pendently of epicardial coronary artery stenoses (3)—as
might have been the case in the population studied by Fang
et al. (2), where a part had been screened with coronary
angiography and showed normal coronary arteries. Some-
times the evidence of coronary microangiopathy is associ-
ated with signs of LV diastolic dysfunction in the absence of
systolic dysfunction (5). Contractile impairment and heart
dysfunction in chronic diabetes can be also due to subcel-
lular remodeling and calcium-handling abnormalities, with
defects in sarcoplasmatic reticulum and sarcolemmal cal-
cium transport due to the accumulation of lipid metabolites
in the membrane (9).
Diabetic microvascular disease and the alternative isch-
emic cascade. Fang et al. (2) described a normal hyperki-
netic response during dobutamine stress in diabetic hearts.
However, this evidence does not rule out small vessel disease
in diabetic hearts. In fact—as counterintuitive as it might
seem—it is now recognized that a pure “microvascular”
disease leading to reduced coronary flow reserve with
angiographically normal coronary arteries is associated with
a supernormal LV function during stress (10). In diagnostic
practice with stress imaging, not all patients follow the
reassuring paradigm proposed by the classical “ischemic
cascade.” Electrocardiographic changes may often occur
with typical chest pain, in the absence of echocardiographic
changes, and can be accompanied by real, not artifactual,
reversible perfusion defects (10–12). In fact, the typical
behavior of microvascular disease during stress testing is the
frequent induction of chest pain, ST-segment depression,
and also perfusion abnormalities without regional or global
wall motion changes (10).
The sequence of events is therefore strikingly different
from the classic ischemic cascade found during stress testing
in the presence of a coronary stenosis. The LV is hyperdy-
namic during stress, despite the frequent occurrence of chest
pain and ST segment depression: “too good to be ischemic,”
at least when the usual pattern of classic ischemia due to
coronary artery stenosis is considered. Thus, although few
would argue that induced myocardial dysfunction is an
accurate marker of regional ischemia, the presence of
regional abnormal vasodilator reserve may or may not be
associated with ischemia. Our monolithic view of ischemia
mirrored in the classic ischemic cascade should be integrated
by the awareness of the reverse or alternative ischemic
cascade best describing microvascular disease, with echocar-
diographic changes usually being absent during physical or
pharmacologic stress. Not all forms of myocardial ischemia
are the same, and milder patchy degrees of myocardial
ischemia—as those possibly induced in microvascular an-
gina associated with diabetes (11,12)—remain silent in their
mechanical functional manifestations and may represent a
physiologic scotoma of stress echocardiography (10).
The diabetic “cardiomyopathy cascade.” In diabetic pa-
tients, an integrated ultrasound assessment can identify
different stages of disease well before clinical overt cardio-
myopathy (Fig. 1). Early in the natural history of the
disease, some metabolic damage can lead to abnormal
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increased myocardial echodensity (detectable by tissue char-
acterization) and to abnormal subendocardial function (de-
tectable by cyclic backscatter variation) (13,14). This alter-
ation can be associated with abnormal global systolic and
diastolic indices, such as those derived by Doppler (15) or
tissue Doppler imaging, when conventional two-
dimensional echo still gives normal values of ejection frac-
tion. At a more advanced stage, a reduced inotropic reserve
can be observed during exercise (16). In an advanced stage,
wall motion abnormalities—at first regional, and later glob-
al—occur at rest. Somewhere in between, a reduction in
coronary flow reserve can be detected, usually in patients
with some degree of diastolic or systolic dysfunction (5) and
microangiopathic involvement (17).
Within this conceptual framework, stress tissue Doppler
imaging was a reasonable candidate for providing a simple,
quantitative marker of incipient diabetic cardiomyopathy.
Unfortunately, it did not work (2). The baseline differences
in peak myocardial and early diastolic velocity (18) disap-
peared during stress (2). This may be related to the type of
index employed. Tissue Doppler imaging represents an
attractive technique for quantifying stress echo because: 1) it
permits subtle segmental assessment of myocardial function
during cardiac cycle; 2) it compares well versus reference
methods such as sonomicrometry; and 3) it is very sensitive
to inotropic stimulation and ischemic challenge. However,
tissue Doppler imaging does have limitations (19). Firstly,
the amplitude of the estimated velocity is dependent on the
angle at which the region is imaged. Secondly, overall heart
motion, rotation, and contraction of adjacent myocardial
segments will influence regional velocity estimates. There-
fore, both the angle and motion of adjacent segments can
change during dobutamine stress, diluting the information
obtained by tissue Doppler imaging in this setting.
The results of Fang et al. (2) are therefore not in
agreement with their very reasonable working hypothesis of
finding an abnormal stress response in patients with baseline
abnormalities, and this adds strength and value to their
work. In the field of leading edge innovations, many new
technologies are presented as the ultimate breakthrough
before their inaccuracies are recognized. Due to the pro-
technology bias of modern medicine, we, as physicians, are
encouraged to trust and to use (and to buy) technologies
long before their clinical incremental value has been shown.
Illogically, technologies are first sold and only later assessed,
sometimes with very disappointing results (20). The study
Figure 1. The hypothetical echocardiographic cascade of diabetic cardiomyopathy. Metabolic changes (non-enzymatic glycation?) cause an early structural
alteration (with inappropriate accumulation of myocardial connective tissue?), which induces subclinical disturbances: variation in regional echodensity,
blunted cyclic gray level variation, alterations in diastolic function, alterations in systolic function, reduced coronary flow reserve, reduction of inotropic
reserve, and finally, the onset of resting wall motion abnormalities—regional at first and global at a later stage. Only at this latter stage, the clinically overt
manifestations of diabetic cardiomyopathy appear. Each of these variables is detected by its specific ultrasound technology. Myocardial structural alterations
can be detected with tissue characterization; diastolic and systolic abnormalities by tissue Doppler imaging; coronary flow reserve with transthoracic Doppler
flowmetry of the left anterior descending coronary artery (LAD); inotropic reserve reduction by stress echo; and regional dyssynergies by resting
two-dimensional (2D) echo.
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of Fang et al. (2) is important also because of the negative
finding, showing that there was a normal stress response
detected with tissue Doppler imaging. But, it also has an
equally important positive finding, showing that resting
tissue Doppler signal is a very early event in diabetic
cardiomyopathy (18), perhaps early enough to have a
therapeutic impact.
Detection of diabetic cardiomyopathy: the importance of
being earliest. Diagnosing pre-clinical diabetic cardiomy-
opathy early through cardiac ultrasound is not only impor-
tant but also may turn out also to be essential for the
appropriate clinical testing of new therapeutic approaches.
In animal models, high concentrations of plasma glucose
can induce a loss in number and hypertrophy of myocytes,
leading to the cardiomyopathy, diastolic dysfunction, loss of
heart mass, and cardiac insufficiency that accompany diabe-
tes. In cardiac myocytes, hyperglycemia amplifies the pres-
ence of renin and angiotensin. Angiotensin II binds to its
receptor, AT1, and induces apoptosis, which probably
contributes to cardiac myopathy (21). Changes in cardiac
systolic and diastolic function induced by diabetes can be
well monitored by experimental echocardiography, which
assesses the efficacy of therapeutic interventions such as
restoring cardiac metabolism in transgenic diabetic mice
with human glucose transporter 4 (22).
According to studies performed in humans, apoptosis of
myocytes, endothelial cells, and fibroblasts in the diabetic
heart was characterized by an 85-fold, a 61-fold, and a
26-fold increase, respectively (23). Diabetes upregulates the
renin-angiotensin system, which may contribute to the
development of a dilated cardiomyopathy, whereas locally,
angiotensin II may lead to oxidative damage, activating
cardiac cell death. These advances in the basic understand-
ing of cellular mechanisms underlying diabetic cardiomyop-
athy might be relevant to therapy. Tight glycemic control
could be a strategy to prevent cardiomyopathy, along with
other pharmacologic treatment—for instance, angiotensin-
converting enzyme inhibitors, selective blockers of angio-
tensin II type 1 receptors, or aldosterone antagonists at low
non-diuretic doses (24).
Any clinical study aimed at assessing the prevention of
dilated cardiomyopathy should probably have a target pop-
ulation of diabetic patients with early, incipient cardiomy-
opathy. Clinically overt dilated cardiomyopathy may already
be beyond the point of no return of advanced structural
myocardial alterations—hardly reversible with any form of
treatment.
Conclusions. Ultrasound could provide the ideal probe for
the early detection of subtle changes and monitoring of the
natural history and the effects of therapeutic interventions
over time. But still research goes on as the debate remains
over which parameter is best: tissue characterization, non-
invasively assessed coronary flow reserve, tissue Doppler,
diastolic or systolic function, regional or global function,
baseline assessment, or evaluation during stress. Nonethe-
less, the use of ultrasound will inevitably increase as it
assesses, in a methodologically robust way, diabetic cardio-
myopathy with a relatively inexpensive, ecologically sustain-
able, biohazard-free technology (25) that also can detect
early and evaluate the efficacy of therapeutic interventions in
these patients through serial follow-ups.
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